Abstract
Isoflavones (ISO) are bioactive food ingredients of the traditional East Asian diet and currently discussed as alternatives to classical hormone replacement therapies. The initial „health claim“ towards menopausal applications of ISO containing products stems from epidemiologic observations as soy isoflavones seem to reduce the prevalence of hormone-dependent cancers, e.g. endometrial, breast or prostate cancer. These claims were further supported by the observation, that neonatal exposure to ISO can prevent DMBA induced mammary cancer in rats. Although there are numerous studies on ISO phytoestrogens, experimental animal data on their long-term effects eventually supporting or disapproving observations in epidemiological studies are scarce. Therefore we and others [1] performed dietary exposure studies in rats
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
